Nvidia collaboration Channel Insider content and product recommendations are editorially independent. We may make money when you click on links to our partners. View our editorial policy here .
Multinational tech giant NVIDIA made a handful of recent announcements that highlight its participation in the AI revolution permeating the healthcare industry.
During a press briefing, Kimberly Powell, Vice President of Healthcare at NVIDIA, broke down NVIDIA’s recent moves in the AI and healthcare space, including collaborating with other entities to enable new products and services with AI.
NVIDIA is fostering partnerships with several organizations as the convergence of AI, accelerated computing, and biological data turns healthcare into the largest technology industry. These partnerships include collaborations with IQVIA for clinical trials, Illumina for genomics insights, the Mayo Clinic for pathology models, and the Arc Institute for biology AI models.
Currently, NVIDIA’s AI enterprise platform supports over 1,000 healthcare startups developing AI agents. NVIDIA’s newest collaborations
IQVIA partnership to boost drug and medical device deployment
Among the announcements include clinical research leader IQVIA partnering with NVIDIA in their AI foundry and factory platforms and services to accelerate their development and deployment of AI agents for their over 10,000 customers across healthcare and life sciences.
“IQVIA and the NVIDIA AI Foundry is going to really help IQVIA streamline custom model development using NVIDIA NIMs, our newly announced Llama Nemotron models, our AI blueprints as reference workflows, and the NEMO platform on dedicated capacity of NVIDIA DGX cloud,” said Powell. “NVIDIA’s collection of models, AI agents, and reference workflows will be made available through their IQVIA healthcare-grade AI solutions to its global pharmaceutical, biotech, and med device customers.”
Powell says that the partnership is going to focus initially on clinical trials. The partnership will accelerate trial execution while significantly reducing the administrative burden through the deployment of agents of all kinds.NVIDIA will also be releasing its latest generation of molecular generation NIM called GenMol, a goal-directed molecular generation NIM that is going to be utilized for virtual screening. Arc Institute collaboration to scale biology AI models Arc Institute, a California-based research organization, will be collaborating with NVIDIA to develop […]
Ketamine shows promise for treatment-resistant PTSD in psychedelic-style therapy settings
[Imagen 3] Follow PsyPost on Google News A new study
